N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Sponsor: Merck Sharp & Dohme LLC • ClinicalTrials.gov ID: NCT06780111

Registry updated: 2026-10-16
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts. Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. Researchers want to learn about giving pembrolizumab and investigational agents, with or without chemotherapy to treat ESCC. Ifinatamab deruxtecan (I-DXd), is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn about the safety of investigational agents and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.

Interventions

  • Pembrolizumab (Biological)
    IV infusion
  • I-DXd (Biological)
    IV infusion
  • Leucovorin (Drug)
    IV infusion
  • Levoleucovorin (Drug)
    IV infusion
  • 5-Fluorouracil (5-FU) (Drug)
    IV Infusion
  • Oxaliplatin (Drug)
    IV infusion
  • Sacituzumab tirumotecan (Biological)
    IV infusion
  • Rescue Medication (Drug)
    Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label

Eligibility criteria

Inclusion Criteria The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic squamous cell carcinoma of the esophagus in first-line (1L) setting. * Has measurable disease per RECIST 1.1 as assessed by the local site. investigator or designee/radiology assessment and verified by BICR. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions. * Has had AEs due to previous anticancer therapies that have recovered to ≤Grade 1 or baseline. Endocrine-related AEs that are adequately treated with hormone replacement are elegible. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART). * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Has adequate organ function. Exclusion Criteria The main exclusion criteria include but are not limited to the following: * Has had systemic anticancer therapy for locally advanced unresectable or metastatic esophageal cancer. * Has tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula. * Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention. * Has clinically significant corneal disease, history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. * Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor. * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention. * Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids. * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed. * Has inadequate cardiac function assessed as by a corrected QT interval by Fredericia (QTcF) value ≥470 msec. * Has clinically significant cardiovascular disease within 6 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability. * Has peripheral neuropathy ≥ Grade 2. * Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention. * Has known additional malignancy that is progressing or has required active treatment within the past 3 years. * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has active autoimmune disease that has required systemic treatment in the past 2 years. * Has had a history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), has a current diagnosis of ILD, or has clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out. * Has active infection requiring systemic therapy. * Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder.

Conditions

Esophageal Squamous Cell Carcinoma

Locations

  • UPMC Hillman Cancer Center ( Site 1904) — Pittsburgh, Pennsylvania, United States
  • Liga Norte Riograndense Contra o Cancer ( Site 1301) — Natal, Rio Grande do Norte, Brazil
  • Hospital Nossa Senhora da Conceicao ( Site 1300) — Porto Alegre, Rio Grande do Sul, Brazil
  • IBCC - Instituto Brasileiro de Controle do Cancer ( Site 1303) — São Paulo, São Paulo, Brazil
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1302) — São Paulo, Brazil
  • Clínica Puerto Montt ( Site 1406) — Port Montt, Los Lagos Region, Chile
  • Fundación Arturo López Pérez ( Site 1400) — Santiago, Region M. de Santiago, Chile
  • Centro de Oncología de Precisión ( Site 1402) — Santiago, Region M. de Santiago, Chile
  • Clínica UC San Carlos de Apoquindo ( Site 1403) — Santiago, Region M. de Santiago, Chile
  • Bradfordhill ( Site 1401) — Santiago, Region M. de Santiago, Chile
  • Bradford Hill Norte ( Site 1405) — Antofagasta, Chile
  • The Second Affiliated Hospital of Anhui Medical University ( Site 9511) — Hefei, Anhui, China
  • Beijing Cancer Hospital ( Site 9500) — Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Xiamen University ( Site 9503) — Xiamen, Fujian, China
  • Henan Cancer Hospital ( Site 9509) — Zhengzhou, Henan, China
  • Xuzhou Central Hospital ( Site 9512) — Xuzhou, Jiangsu, China
  • The First Affiliated Hospital of Nanchang University ( Site 9505) — Nanchang, Jiangxi, China
  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 9000) — Brno, Brno-mesto, Czechia
  • C.H.R.U. de Brest - Hopital Cavale Blanche ( Site 9104) — Brest, Finistere, France
  • CHU Lille - Institut Coeur Poumon ( Site 9100) — Lille, Nord, France
  • Pitie Salpetriere University Hospital ( Site 9102) — Paris, France
  • NCT-Department of Medical Oncology ( Site 1809) — Heidelberg, Baden-Wurttemberg, Germany
  • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 1807) — Erdgeschoss, Free and Hanseatic City of Hamburg, Germany
  • Universitaetsklinikum Duesseldorf ( Site 1808) — Düsseldorf, North Rhine-Westphalia, Germany
  • Universitätsklinikum Carl Gustav Carus - Medical Oncology ( Site 1806) — Dresden, Saxony, Germany
  • Ospedale San Raffaele-Oncologia Medica ( Site 9201) — Milan, Lombardy, Italy
  • Istituto Oncologico Veneto IRCCS ( Site 9202) — Padova, Veneto, Italy
  • Aichi Cancer Center ( Site 9702) — Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East ( Site 9701) — Kashiwa, Chiba, Japan
  • National Cancer Center Hospital ( Site 9700) — Chūō, Tokyo, Japan
  • Oslo Universitetssykehus Radiumhospitalet ( Site 1501) — Oslo, Norway
  • National University Hospital ( Site 9800) — Singapore, Central Singapore, Singapore
  • National Cancer Center ( Site 9902) — Goyang-si, Kyonggi-do, South Korea
  • Asan Medical Center ( Site 9901) — Seoul, South Korea
  • Samsung Medical Center ( Site 9900) — Seoul, South Korea
  • Kantonsspital Graubuenden ( Site 1700) — Chur, Kanton Graubünden, Switzerland
  • Hopitaux Universitaires de Geneve HUG. ( Site 1701) — Geneva, Switzerland
  • Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1009) — Kaoshiung, Kaohsiung, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital ( Site 1003) — Kaohsiung City, Taiwan
  • China Medical University Hospital ( Site 1007) — Taichung, Taiwan
  • National Cheng Kung University Hospital ( Site 1001) — Tainan, Taiwan
  • National Taiwan University Hospital ( Site 1000) — Taipei, Taiwan
  • Taipei Veterans General Hospital ( Site 1005) — Taipei, Taiwan
  • Chang Gung Memorial Hospital - Linkou Branch ( Site 1006) — Taoyuan, Taiwan
  • Ramathibodi Hospital ( Site 1103) — Ratchathewi, Bangkok, Thailand
  • Songklanagarind hospital ( Site 1101) — Hat Yai, Changwat Songkhla, Thailand
  • Hacettepe Universite Hastaneleri ( Site 9401) — Ankara, Turkey (Türkiye)
  • Memorial Ankara Hastanesi ( Site 9406) — Ankara, Turkey (Türkiye)
  • Ankara Bilkent Şehir Hastanesi ( Site 9403) — Ankara, Turkey (Türkiye)
  • Atatürk Üniversitesi ( Site 9405) — Erzurum, Turkey (Türkiye)
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record